Teduglutide

What is Teduglutide?#

Teduglutide (marketed as Gattex in the US and Revestive in Europe) is a recombinant analog of human glucagon-like peptide-2 (GLP-2), a 33-amino acid intestinotrophic hormone that promotes growth and repair of the intestinal mucosa. It was approved by the FDA in December 2012 and by the EMA in 2012 for the treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral nutrition. Pediatric approval (ages 1 year and older) followed in 2019.

Teduglutide represents a first-in-class therapy that addresses the underlying pathophysiology of intestinal failure by enhancing intestinal adaptation rather than simply managing symptoms.

Mechanism of Action#

Teduglutide binds to the GLP-2 receptor (GLP-2R), which is expressed primarily on intestinal subepithelial myofibroblasts and enteric neurons. Receptor activation triggers a cascade of downstream effects:

1. Crypt cell proliferation: Stimulates intestinal stem cells and transit-amplifying cells in the crypts of Lieberkuhn, expanding the regenerative compartment
2. Villus elongation: Increases villus height, thereby expanding the absorptive surface area of the small intestine
3. Anti-apoptotic effects: Inhibits programmed cell death in both crypt and villus epithelial cells, prolonging the lifespan of absorptive enterocytes
4. Enhanced blood flow: Increases intestinal and portal blood flow, supporting nutrient transport
5. Reduced gastric emptying: Slows gastric motility, allowing more time for nutrient digestion and absorption

The GLP-2 receptor signals through subepithelial myofibroblasts to release IGF-1 and other growth factors via PI3K/Akt-dependent pathways. This indirect signaling cascade, rather than direct action on epithelial cells, explains the trophic effects on the mucosa.

Clinical Significance#

Short bowel syndrome-associated intestinal failure (SBS-IF) is a devastating condition in which patients cannot absorb sufficient nutrients from the remaining intestine after surgical resection. These patients depend on parenteral nutrition (PN), which carries significant risks including catheter-related bloodstream infections, liver disease, loss of venous access, and reduced quality of life.

Teduglutide addresses this by promoting intestinal adaptation, enabling patients to reduce or eliminate their dependence on parenteral support. In clinical trials and long-term real-world use, teduglutide has demonstrated sustained reductions in PN requirements for up to 10 years.

Important Considerations#

Teduglutide requires monitoring for potential complications including intestinal polyps, biliary and pancreatic disease, and intestinal obstruction. Colonoscopy is recommended before initiation, after 1-2 years, and then every 5 years during treatment. The drug carries a boxed warning regarding the potential acceleration of neoplastic growth.

Key Research Findings#

Teduglutide Reduces Need for Parenteral Support Among Patients with Short Bowel Syndrome with Intestinal Failure, published in Gastroenterology (Jeppesen PB et al., 2012; PMID: 22982184):

• The study demonstrated responders of 63% in teduglutide group vs 30% placebo
• The study showed mean PN volume reduction of 4.4 L/week with teduglutide vs 2.3 L/week placebo

Related Reading#

• Teduglutide research studies and evidence
• Teduglutide dosing protocols
• Teduglutide side effects profile
• BPC-157 research guide
• GLP-1 research guide